AnaptysBio, Inc (ANAB) stock

ANABNasdaqPharmaceutical PreparationsFiscal year ends June 30

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 9/30

$49.24+2.63 (+5.64%)

Close on Oct 19, 2026Market cap $1.73BP/E –Yield –

AnaptysBio gross margin

Gross margin is gross profit as a percentage of revenue.

AnaptysBio has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ANAB.

Revenue growth13.0% · median 65.7%

Operating margin155.6% · median -61.7%

Net margin96.3% · median -58.8%

Advertisement
300 × 250

See a number that looks wrong?